Shares of Kala Pharmaceuticals (NASDAQ: KALA) plunged in morning trading on Friday after shares of the clinical-stage biopharmaceutical company started trading on a split-adjusted basis today after the markets opened.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Kala announced on Thursday that it will effect a reverse stock split in the ratio of “1 post-split share for every 50 pre-split shares.”
The reverse stock split will reduce Kala’s common stock outstanding from 73.20 million shares to around 1.46 million shares, subject to adjustment for the rounding up of fractional shares.
